ATE480265T1 - Verwendung von zahnfleischfibroblasten zur behandlung von vaskulären zellen - Google Patents

Verwendung von zahnfleischfibroblasten zur behandlung von vaskulären zellen

Info

Publication number
ATE480265T1
ATE480265T1 AT05786212T AT05786212T ATE480265T1 AT E480265 T1 ATE480265 T1 AT E480265T1 AT 05786212 T AT05786212 T AT 05786212T AT 05786212 T AT05786212 T AT 05786212T AT E480265 T1 ATE480265 T1 AT E480265T1
Authority
AT
Austria
Prior art keywords
fibroblas
dental
vascular cells
treat vascular
treat
Prior art date
Application number
AT05786212T
Other languages
English (en)
Inventor
Antoine Lafont
Bruno Gogly
Original Assignee
Univ Paris Descartes
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Descartes, Assist Publ Hopitaux De Paris filed Critical Univ Paris Descartes
Application granted granted Critical
Publication of ATE480265T1 publication Critical patent/ATE480265T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05786212T 2004-07-02 2005-07-01 Verwendung von zahnfleischfibroblasten zur behandlung von vaskulären zellen ATE480265T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0407357A FR2872431B1 (fr) 2004-07-02 2004-07-02 Utilisation de fibroplastes gingivaux en therapie cellulaire vasculaire
PCT/FR2005/001690 WO2006013261A2 (fr) 2004-07-02 2005-07-01 Utilisation de fibroblastes gingivaux en therapie cellulaire vasculaire.

Publications (1)

Publication Number Publication Date
ATE480265T1 true ATE480265T1 (de) 2010-09-15

Family

ID=34946541

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05786212T ATE480265T1 (de) 2004-07-02 2005-07-01 Verwendung von zahnfleischfibroblasten zur behandlung von vaskulären zellen

Country Status (11)

Country Link
US (2) US8119122B2 (de)
EP (1) EP1773420B1 (de)
JP (1) JP4891903B2 (de)
AT (1) ATE480265T1 (de)
AU (1) AU2005268746B2 (de)
CA (1) CA2572554C (de)
DE (1) DE602005023468D1 (de)
DK (1) DK1773420T3 (de)
ES (1) ES2354220T3 (de)
FR (1) FR2872431B1 (de)
WO (1) WO2006013261A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2663690T3 (es) 2006-08-10 2018-04-16 Université Paris Descartes Método para tratar heridas de piel
EP1972685B1 (de) 2007-03-20 2015-09-02 Université Paris Descartes Kulturmedium für Zahnfleischfibroblasten
JP5476515B2 (ja) * 2007-10-09 2014-04-23 ユニヴェルシテ・パリ・デカルト 細胞を投与するデバイス
JP2011526585A (ja) * 2008-03-31 2011-10-13 スカルセル テラピュティク 皮膚の老化の美容的処置法
JP5839467B2 (ja) * 2009-03-06 2016-01-06 ユニベルシテ パリ デカルト 癌を治療するための方法
WO2011012575A1 (en) 2009-07-27 2011-02-03 Scarcell Therapeutics Balloon catheter device
FR3008316B1 (fr) 2013-07-09 2020-01-31 Assistance Publique - Hopitaux De Paris Utilisation de fibroblastes gingivaux dans le traitement de l'alopecie
EP3450548A4 (de) * 2016-04-27 2019-11-20 Rohto Pharmaceutical Co., Ltd. Mesenchymale stammzelle zur expression von mindestens einem zelloberflächenmarker, der aus der gruppe von cd201, cd46, cd56, cd147 und cd165 ausgewählt wurde, und verfahren zur herstellung davon und pharmazeutische zusammensetzung mit der mesenchymalen stammzelle und verfahren zur herstellung davon
EP3541399A1 (de) * 2016-11-18 2019-09-25 Scarcell Therapeutics Zusammensetzungen zur verwendung bei der behandlung von immunerkrankungen
SG11202105105SA (en) 2018-11-30 2021-06-29 Shiseido Co Ltd Composition for treating or preventing skin pigmentation
WO2024189522A1 (en) 2023-03-15 2024-09-19 Scarcell Therapeutics Mammalian cell population and medicaments for cell therapies in mammals and improved cell cultivation methods
AU2024235245A1 (en) 2023-03-15 2025-09-25 Scarcell Therapeutics Sas Mammalian cell population and medicaments for cell therapies in mammals and improved cell cultivation methods
US12351823B2 (en) 2023-03-15 2025-07-08 Scarcell Technologies Mammalian cell population and medicaments for cell therapies in equines and improved cell cultivation methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2678945B2 (ja) * 1989-04-17 1997-11-19 有限会社ナイセム 人工血管とその製造方法及び人工血管用基質
US5891558A (en) * 1994-11-22 1999-04-06 Tissue Engineering, Inc. Biopolymer foams for use in tissue repair and reconstruction
AU3214797A (en) * 1996-05-28 1998-01-05 Regents Of The University Of Michigan, The Engineering oral tissues
AU3118499A (en) * 1998-04-03 1999-10-25 Beth Israel Deaconess Medical Center Soft tissue reconstructor and method of use
AU2001249704A1 (en) * 2000-04-28 2001-11-12 The Regents Of The University Of California Structures useful for bone engineering and methods
US20040101959A1 (en) * 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells

Also Published As

Publication number Publication date
US20120177613A1 (en) 2012-07-12
US8119122B2 (en) 2012-02-21
FR2872431B1 (fr) 2007-07-20
JP2008505164A (ja) 2008-02-21
FR2872431A1 (fr) 2006-01-06
CA2572554C (fr) 2013-09-10
EP1773420A2 (de) 2007-04-18
DK1773420T3 (da) 2011-01-10
CA2572554A1 (fr) 2006-02-09
WO2006013261A3 (fr) 2006-06-15
US8609085B2 (en) 2013-12-17
AU2005268746A1 (en) 2006-02-09
AU2005268746B2 (en) 2011-01-06
ES2354220T3 (es) 2011-03-11
JP4891903B2 (ja) 2012-03-07
DE602005023468D1 (de) 2010-10-21
US20080025954A1 (en) 2008-01-31
EP1773420B1 (de) 2010-09-08
WO2006013261A2 (fr) 2006-02-09

Similar Documents

Publication Publication Date Title
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
DE602004015811D1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
ATE554725T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
ATE530142T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
ATE523196T1 (de) Mitotische kinesinhemmer und verfahren zu ihrer verwendung
DE602005023468D1 (de) Verwendung von zahnfleischfibroblasten zur behandlung von vaskulären zellen
WO2007030743A3 (en) Cochlear implants containing biological cells and uses thereof
DE602004028587D1 (de) ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
ATE555380T1 (de) Verfahren zur änderung des schicksals von zellen
DE602004012816D1 (de) Selbstexpandierbarer Stent und Stenteinbringungssystem zur Behandlung von Gefässerkrankungen
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE602005015862D1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
DE602004022036D1 (de) Verfahren zur behandlung von atherosklerose, dyslipidämie und verwandten erkrankungen und pharmazeutische zusammensetzungen
DE602005019247D1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE487487T1 (de) Verwendung von verbindungen, die die ef-tu- nucleolin wechselwirkung vehindern, zur verhinderung oder behandlung von tularämie
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
DE602005015160D1 (de) Stent-Graft zur Behandlung von Aneurysmen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties